Glitazone drug use by diabetic patients associated with lower risk of primary and secondary brain cancer

Diabetic patients who take anti-diabetic drugs – known as glitazones – long term had a lower risk of primary and secondary brain cancer compared with diabetic patients on other medications, new research led by the University of Bristol has found.